AMT-130 (AAV5-miHTT gene therapy)

Timeline

Study Dates

Start Date

February 2022

Est. Completion

December 2027

Enrollment Target

40 participants

Status

Active (not recruiting)

Study Design

Primary Endpoint

Safety, tolerability, and exploratory efficacy of AMT-130 in European sites, parallel to the US Phase 1/2 program

Registry

ClinicalTrials.gov Record

Registry ID

NCT05243017

Direct Link

Related Treatment

Treatment Being Studied